Patients treated with PCSK9 inhibitors had an absolute increase of incidents diabetes (weighted mean difference) of 1.88 mg/dl (95% CI: 0.91–2.68), which was significantly different from placebo (standardised mean difference 0.166%; 95% CI: 0.143–0.188). Regarding HbA1c levels, compared with baseline, patients treated with PCSK9 inhibitors had a weighted mean difference of 0.032% (0.011–0.050; standardised mean difference 0.096%; 95% CI: 0.074–0.119). Here, PCSK9 is linked to diabetes mellitus.